



**news  
release**

**Enzo Biochem, Inc.**  
527 Madison Avenue  
New York, NY 10022

**For Immediate Release**

Contact: Barry Weiner  
(212) 583-0100

**ENZO BIOCHEM ANNOUNCES AGREEMENT WITH AFFYMETRIX  
TO BE SOLE SUPPLIER OF LABELING AND DETECTION PRODUCTS  
FOR GENECHIP® ARRAYS**

---

FARMINGDALE, NY, May 27, 1998 – Enzo Biochem, Inc. (ASE:ENZ) today announced that Enzo Diagnostics, its wholly owned subsidiary has entered into an agreement with Affymetrix, Inc. under which Enzo will be the sole supplier of specified proprietary nucleic acid labeling and detection products for Affymetrix' GeneChip® arrays worldwide.

Under the terms of the agreement, Affymetrix becomes a nonexclusive worldwide distributor of Enzo nucleic acid labeling and detection kits to be sold together and used with the Affymetrix GeneChip arrays. Enzo manufactures customized kits, based on its patented technology, that meet the specifications of various Affymetrix GeneChip array products for sale to the research market. Affymetrix will package and ship these Enzo products in association with GeneChip arrays.

Enzo's products are used to label and detect the nucleic acid sequences that are being analyzed with the GeneChip® array.

In addition, Affymetrix will be allowed to use certain Enzo proprietary products and technology to optimize existing GeneChip products, and to develop new GeneChip products. Certain rights from these developments will be retained by each company.

Affymetrix has developed and intends to establish its GeneChip system as the platform of choice for analyzing and managing complex genetic information in order to improve the diagnosis, monitoring and treatment of disease. The GeneChip system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner and other instruments to process the probe arrays and software to analyze and manage genetic information.

Enzo Biochem, a pioneer and leader in the development of nonradioactive nucleic acid labeling and detection technologies, holds more than 100 worldwide  
-more-

patents and produces a wide range of proprietary products, that are used in the global medical research market and are expected to have broad application in the clinical diagnostic market.

"This agreement is further recognition of Enzo's position as the leading developer of nucleic acid labeling and detection systems," said Elazar Rabbani, Ph.D., Chairman and CEO of Enzo Biochem. "We believe that a combination of Enzo's labeling and detection products together with Affymetrix' GeneChip arrays will provide a compelling combination in the rapidly developing area of gathering and analyzing genetic information, and we are pleased to be part of this development."

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.

# # #